Bio-Rad Laboratories, Inc.

BIO Healthcare Medical Devices

Bio-Rad Laboratories, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.6 billion, up 0.65% from fiscal 2024.

Revenue
+0.52%
EPS
+234.9%
Free cash flow
+8.07%
Total debt
+0.11%

Quarter to September 2026, against a year earlier

381.91 12.91 +3.50%
Market cap
$9.9B
P/E
9.7×
Fwd P/E
44.7×
Dividend yield
—
F-score
5/9
Altman Z
3.20
Beneish M
−2.29
Dividend safety
n/a

Bio-Rad Laboratories, Inc. (BIO) Operating cash flow

Alert me on Operating cash flow

Bio-Rad Laboratories, Inc.'s operating cash flow for fiscal 2025 was $532.2M, up 16.9% from $455.2M in fiscal 2024. Over the twelve months to 30 September 2026 it was $468.1M. Over the past ten years it has ranged from $104.1M (fiscal 2017) to $669.5M (fiscal 2021); the current reading is higher than 82% of that period. Operating cash flow has risen for 3 consecutive fiscal years. Bio-Rad Laboratories, Inc. ranks 15th of 149 Medical Devices companies by operating cash flow.

Operating cash flow, annual

Embed this chart

Annual newest first

Period Operating cash flow Change
FY2025 $532.2M 16.92%
FY2024 $455.2M 21.42%
FY2023 $374.9M 92.85%
FY2022 $194.4M (70.96%)
FY2021 $669.5M 14.44%
FY2020 $585.0M 27.75%
FY2019 $457.9M 60.39%
FY2018 $285.5M 174.15%
FY2017 $104.1M (51.80%)
FY2016 $216.1M 16.03%

Quarterly newest first

Period Operating cash flow Change
Sep 2026 $96.4M (2.33%)
Jun 2026 $98.7M (8.70%)
Mar 2026 $108.1M (34.45%)
Dec 2025 $164.9M 36.39%
43 more quarters

Against its own ten years

Low $104.1M High $669.5M
Ten-year median $374.9M
Current reading's percentile 82

Operating cash flow against peers

What Operating cash flow is

Operating Cash Flow shows how much cash a company’s day-to-day business actually brings in, after paying suppliers, staff and taxes.

Reported line item

The full definition of Operating cash flow →

More on BIO